39256-83-2

Basic information

• Product Name: (S)-2-Amino-3-(4-fluorophenyl)propionicacidethylester
• Synonyms: (S)-2-Amino-3-(4-fluorophenyl)propionicacidethylester
• CAS NO: 39256-83-2
• Molecular Formula: C₁₁H₁₄FNO₂
• Molecular Weight: 0
• Mol File: 39256-83-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-2-Amino-3-(4-fluorophenyl)propionicacidethylester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-Amino-3-(4-fluorophenyl)propionicacidethylester(39256-83-2)
• EPA Substance Registry System: (S)-2-Amino-3-(4-fluorophenyl)propionicacidethylester(39256-83-2)

Safety Data

• Hazardous Substances Data: 39256-83-2(Hazardous Substances Data)

Usage

Description

(S)-2-Amino-3-(4-fluorophenyl)propionic acid ethyl ester is an organic compound and a chiral molecule belonging to the class of amino acids. It is an ester derivative of the amino acid phenylalanine, featuring a fluorine atom attached to the benzene ring. (S)-2-Amino-3-(4-fluorophenyl)propionicacidethylester has two enantiomers, (S)and (R)-, with the (S)-enantiomer exhibiting potential pharmacological properties, including analgesic and anti-inflammatory effects, making it a promising candidate for the development of new drugs for pain management.

Uses

Used in Pharmaceutical Research:
(S)-2-Amino-3-(4-fluorophenyl)propionic acid ethyl ester is used as a chiral building block for the synthesis of various pharmaceutical compounds due to its unique structure and potential pharmacological properties.
Used in Drug Development:
(S)-2-Amino-3-(4-fluorophenyl)propionic acid ethyl ester is used as a key intermediate in the development of new drugs for pain management, specifically targeting its analgesic and anti-inflammatory effects.
Used in the Synthesis of Enantiomers:
(S)-2-Amino-3-(4-fluorophenyl)propionic acid ethyl ester is used as a starting material for the synthesis of its enantiomers, (S)and (R)-, which can have different biological activities and potential applications in various fields.
Used in the Development of Chiral Compounds:
(S)-2-Amino-3-(4-fluorophenyl)propionic acid ethyl ester is used as a model compound for studying the properties and applications of chiral molecules in the pharmaceutical industry, as well as in other fields where chirality plays a crucial role.

Upstream product

• 380449-51-4 ethyl (2S)-2-[[(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate 
• 64-17-5 ethanol 
• 1132-68-9 L-4-fluorophenylalanine 

Relevant articles and documents

Aminopeptidase expression in multiple myeloma associates with disease progression and sensitivity to melflufen

Multiple myeloma (MM) is characterized by extensive immunoglobulin production leading to an excessive load on protein homeostasis in tumor cells. Aminopeptidases contribute to proteolysis by catalyzing the hydrolysis of amino acids from proteins or peptides and function downstream of the ubiquitin–proteasome pathway. Notably, aminopeptidases can be utilized in the delivery of antibody and peptide-conjugated drugs, such as melflufen, currently in clinical trials. We analyzed the expression of 39 aminopeptidase genes in MM samples from 122 patients treated at Finnish cancer centers and 892 patients from the CoMMpass database. Based on ranked abundance, LAP3, ERAP2, METAP2, TTP2, and DPP7 were highly expressed in MM. ERAP2, XPNPEP1, DPP3, RNPEP, and CTSV were differentially expressed between relapsed/refractory and newly diagnosed MM samples (p a substrate for aminopeptidases LAP3, LTA4H, RNPEP, and ANPEP. The sensitivity of MM cell lines to melflufen was reduced by aminopeptidase inhibitors. These results indicate critical roles of aminopeptidases in disease progression and the activity of melflufen in MM.

Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents

A method for the treatment of emesis in a mammal, which method comprises administering to said mammal an emesis inhibiting amount of a compound which depletes serotonin in the brain of mammals; among which are compounds having the formula: STR1 wherein, R is selected from hydrogen, loweralkyl, trifluoromethyl, carboxyl, or loweralkoxycarbonyl; R1 and R2 are hydrogen or loweralkyl; Z is trifluoromethyl or halogen; the optical isomers and pharmaceutically acceptable salts thereof; two of the preferred compounds of the invention are fenfluramine and norfenfluramine.